Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Current Assets (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Current Assets for 6 consecutive years, with $315.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 46.44% year-over-year to $315.4 million, compared with a TTM value of $315.4 million through Dec 2025, down 46.44%, and an annual FY2025 reading of $315.4 million, down 46.44% over the prior year.
  • Current Assets was $315.4 million for Q4 2025 at Keros Therapeutics, down from $588.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $588.9 million in Q4 2024 and bottomed at $226.1 million in Q3 2021.
  • Average Current Assets over 5 years is $326.7 million, with a median of $304.4 million recorded in 2023.
  • The sharpest move saw Current Assets soared 69.57% in 2024, then crashed 46.44% in 2025.
  • Year by year, Current Assets stood at $251.4 million in 2021, then rose by 13.65% to $285.8 million in 2022, then rose by 21.53% to $347.3 million in 2023, then surged by 69.57% to $588.9 million in 2024, then plummeted by 46.44% to $315.4 million in 2025.
  • Business Quant data shows Current Assets for KROS at $315.4 million in Q4 2025, $588.9 million in Q4 2024, and $463.1 million in Q1 2024.